Related Experiment Video

Updated: May 16, 2026

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

[Neuropathology of mild cognitive impairment]

Masaki Takao1

  • 1Department of Neuropathology (The Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology.

Rinsho Shinkeigaku = Clinical Neurology
|December 1, 2012
PubMed

Insights

Mild cognitive impairment (MCI) exists between normal cognition and dementia, with a 10-15% annual conversion rate. Understanding MCI

Area of Science:

  • Neurology
  • Pathology
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) represents a transitional stage between normal cognition and dementia.
  • The annual conversion rate from MCI to dementia is estimated between 10-15%.
  • Not all individuals with MCI progress to dementia.

Purpose of the Study:

  • To categorize MCI based on clinical presentation.
  • To explore the diverse underlying pathologies associated with different MCI subtypes.
  • To emphasize the importance of understanding neuropathologic complexity for early dementia intervention.

Main Methods:

  • Review of existing studies on MCI classification and neuropathology.
  • Categorization of MCI into amnestic and non-amnestic types, with single or multiple domain involvement.
  • Analysis of neuropathologic findings in MCI, including protein accumulations and cerebrovascular contributions.

Main Results:

  • MCI is classified into four categories: amnestic-MCI, amnestic-MCI with multiple domains, non-amnestic-MCI with single domain, and non-amnestic-MCI with multiple domains.
  • Underlying pathologies vary by MCI subtype, including Alzheimer's disease (AD), cerebrovascular disorders (CVDs), and metabolic diseases.
  • Neuropathologic evidence reveals diverse protein pathologies (tau, amyloid beta, α-synuclein, TDP-43, FUS) and contributions from CVDs and hippocampal sclerosis.

Conclusions:

  • MCI is a heterogeneous condition with varied underlying pathologies.
  • Recognizing the complexity of neuropathologic alterations in MCI is crucial for effective early intervention strategies.
  • Further research into the diverse pathologies of MCI can improve diagnostic accuracy and treatment approaches for dementia.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...